XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results